Bardy Diagnostics Selected as Winner of the MedTech Breakthrough Award For Best New Diagnostic Technology

Bardy Diagnostics, a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has recognized the Carnation Ambulatory Monitor (CAM™) with the "Best New Diagnostic Technology" award in the 2019 MedTech Breakthrough Awards program. Bardy Diagnostics earned the distinction for its innovative P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection technology.

Read More
HealthQuest Capital Closes on $440 Million Fund to Invest in Growth-Stage Companies Optimizing Value in Healthcare

HealthQuest Capital, a growth capital firm investing in companies that optimize value in healthcare, today announced the close of HealthQuest Partners III, L.P. at $440 million, oversubscribed and closed at the hard cap. Fund III will be invested in commercial-stage companies delivering innovation across all sectors of the healthcare industry to improve patient outcomes, enhance efficiency and reduce costs.

Read More
Avedro Announces Pricing of Initial Public Offering

HealthQuest portfolio company Avedro, Inc. (Nasdaq: AVDR), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share, for total gross proceeds of $70.0 million.

Read More
AvedroRandy Scott2019
HealthQuest Co-Leads Investment into Etairos

HealthQuest has made an equity investment in Etairos Health. Etairos an in-home senior care company providing non-skilled and skilled care primarily to the senior population. Etairos acquires selected home care agencies that fit well with its care philosophy and business model, integrates and then expands them, allowing for the creation of a leading regional home care provider. 

Read More
Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update

Read More
Castle Biosciences announces Medicare coverage for the DecisionDx-Melanoma test in cutaneous melanoma

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.

Read More